Abstract: A method and kit are provided herein for determining the ADAMTS-13 activity in a sample. The method comprises contacting the sample with a von Willebrand factor (VWF) polypeptide which has been coupled to a reporter enzyme, such as glucose-6-phosphate dehydrogenase (G6PDH).

Abstract: Disclosed herein are compositions and methods for removing interfering substances from biological samples, biochemical assays, or reagents used in biological samples using porous liposomes that capture and in some instances enrich said interfering substances within the liposomes.

Abstract: Methods for detection and quantitative measurement of proteins with a Coomassie Brilliant Blue Assay with improved sensitivity and maintaining high linearity over a broad measuring range are provided herein. In particular, a method of detecting a protein in a protein-containing sample is provided. The method includes providing a sample including a protein, a reagent including Coomassie Brilliant Blue and having a pH between 0.85 and 1.1, combining the sample and the reagent, and determining absorption at first and second wavelength to determine the amount of protein in the sample. The ratio of the absorption value at the first wavelength between about 580 to 620 nm to the absorption value at the second wavelength between about 520 to 370 nm is used in the spectral photometric determination of the amount of protein.

Abstract: The disclosure provides an in vitro diagnostic method that is sensitive and accurate for detection and quantification of targets of interest that are associated with disease. There is an ongoing need for a highly sensitive detection system. In addition to the methods, stable complexes and kits comprising the components necessary to perform the disclosed detection methods are described.

Abstract: The present invention relates to the detection and quantitative measurement of proteins with the Coomassie Brilliant Blue Assay with improved sensitivity and maintaining high linearity over a broad measuring range. In particular the present invention relates to a method of detecting a protein in a protein-containing sample, comprising providing a sample comprising a protein, a reagent comprising Coomassie Brilliant Blue, combining the sample and the reagent and determining of the absorption to determine the amount of protein in the sample, wherein the pH-value of the reagent is between pH-value 0.85 and pH-value 1.1, and the ratio of the absorption value at a first wavelength of between about 580 to 620 nm to the one at a second wavelength of between about 520 to 370 nm is used in the spectral photometric determination of the amount of protein.

Abstract: The present invention relates to a method for optically determining at least one analyte in a sample, in which a deviation from a reference value or the reference curve is evaluated as an indication that the optical determination of the at least one analyte is corrupted by measurement artifacts.

Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.

Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PlGF), especially antibodies directed against the placental growth factor, and production and use thereof.

Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.

Abstract: The present invention relates to a method for optically determining at least one analyte in a sample, in which a deviation from a reference value or the reference curve is evaluated as an indication that the optical determination of the at least one analyte is corrupted by measurement artifacts.

Abstract: A homogeneous method for determining the enzymatic activity of an analyte in a sample permits simultaneous determination of the amount of enzyme in the same reaction mixture and determination of enzyme activators or inhibitors.

Abstract: The invention relates to analytical test systems and analytical methods, in which molecular switches are used for the qualitative and quantitative determination of analytes in a sample, which have a broad application by means of a selection of the molecular switch suitable for the analyte. The molecular switch comprises a probe, preferably a nucleic acid or a nucleic acid derivative, coupled to a catalytic component, preferably an enzyme. The analyse induces a conformation change in the probe, which alters the accessibility for a substrate in the probe to catalytic components and the change in substrate turnover, corresponding to the change in catalytic activity, is measured.

Abstract: A homogeneous method for determining the enzymatic activity of an analyte in a sample permits simultaneous determination of the amount of enzyme in the same reaction mixture and determination of enzyme activators or inhibitors.

Abstract: The present invention relates to a diagnostic method for identifying persons with genetically related hetero- or homozygous expression of the MR I variant of factor VII-activating protease (FSAP). The heterozygous or homozygous presence of an MR I polymorphism can be identified by a differential modulation of the FSAP activity.

Abstract: Disclosed is a rotor-stator homogenization device which is characterized in that a rotor-stator homogenizer is connected to a reaction vessel via a joining system, and/or homogenization surfaces are used, and/or a rotor-stator homogenizer is used that is suitable for transferring material. Also disclosed is a method which utilizes said device and is characterized in that the reproducibility, efficiency, yield, waste disposal, automation of the rotor-stator homogenization, etc. is improved, for example, while the risk of contaminations is reduced.

Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.

Abstract: The invention relates to analytical test systems and analytical methods, in which molecular switches are used for the qualitative and quantitative determination of analytes in a sample, which have a broad application by means of a selection of the molecular switch suitable for the analyte. The molecular switch comprises a probe, preferably a nucleic acid or a nucleic acid derivative, coupled to a catalytic component, preferably an enzyme. The analyte induces a conformation change in the probe, which alters the accessibility for a substrate in the probe to catalytic components and the change in substrate turnover, corresponding to the change in catalytic activity, is measured.

Abstract: The present invention relates to a diagnostic method for identifying persons with genetically related hetero- or homozygous expression of the MR I variant of factor VII-activating protease (FSAP). The heterozygous or homozygous presence of an MR I polymorphism can be identified by a differential modulation of the FSAP activity.

Abstract: The present invention relates to a method and an apparatus for separating substances from or in biological materials.

Abstract: The invention relates to a method and a device for the isolation and purification of nucleic acids. According to the invention, after decomposition of a sample the nucleic acids present in said sample are isolated and purified.